Developer docs
API playgroundTry for free, no card

Search company profiles

Moonlight AI

Full company profile

uuid0008gf4

Namestring
Moonlight AI
Legal namestring
Moonlight AI AG
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Moonlight AI is a Swiss AI diagnostics company, founded in 2022 and headquartered at the Switzerland Innovation Park Basel Area - Jura in Courroux, with operational offices in Basel (engineering, ML, technical program management) and Tunis (clinical operations, data management, engineering). The company builds a computer-vision and deep-learning platform that analyzes whole slide images of hematology and cytology smears to detect genomic biomarkers and complex disease signatures directly from routine imaging, intended to triage and complement conventional molecular testing such as NGS in diagnostic laboratory workflows. Its product surface currently centers on a myelodysplastic syndrome (MDS) detection capability from peripheral blood, published in Annals of Hematology in June 2025, with planned extension to non-small cell lung cancer (NSCLC) and chronic lymphocytic leukemia (CLL). The platform is designed to integrate with diagnostic lab imaging hardware and Laboratory Information Systems via HL7/FHIR/DICOM and is being engineered for on-premises, cloud, or OEM-embedded deployment aligned with ISO 27001, HIPAA, GDPR and FDA/IVDR/CE regulatory requirements.

Moonlight AI is pre-revenue and pre-commercialization. Its economic model is planned Software as a Medical Device (SaMD) licensing integrated into lab imaging hardware and connected to LIS, with go-to-market executed through direct enterprise sales to diagnostic labs and hospitals plus an international clinical consortium that co-develops and validates the platform in real-world settings; no pricing or contract terms are publicly disclosed. The company serves three primary segments: diagnostic laboratories (the B2B buyer), and the user personas of hematologists and pathologists who consume the diagnostic insight. Four founding clinical partners — University of Basel, Universitätsspital Basel, Universitätsspital Zürich and Charité Universitätsmedizin Berlin — support the initial MDS validation, and a Tunis-based Clinical Study Manager is building additional partnerships across MENA and Europe. On May 6, 2026, the company closed a $3.3M USD seed round co-led by Lotus One Investment (Singapore), VP Venture Partners (Switzerland) and MEDIN Fund (Tunisia), with N&V Capital and existing investor QAI Ventures participating, and simultaneously reincorporated from a Swiss GmbH to a Swiss Stock Corporation (Aktiengesellschaft) to position for international commercialization.

Short descriptiontext

Moonlight AI is a Swiss AI diagnostics startup that uses computer vision and deep learning on whole slide images of hematology and cytology smears to detect genomic biomarkers, serving diagnostic laboratories, hematologists, and pathologists with plans for Software as a Medical Device products across MDS, NSCLC and CLL.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCourroux, Switzerland
HQ citystring
Courroux
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI diagnostics software, computational pathology, whole slide imaging, genomic biomarker detection, hematology image analysis
Industry4 codes
PRIMARYHLACANAD
Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
NAICS code2 codes
  • Other Computer Related Services541519
  • Computer Systems Design and Related Services54151
SIC code1 code
  • Services-Prepackaged Software7372
Product category
AI Diagnostics Software
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pre-commercialization software diagnostics (planned)
TypeLicensing Royalties
Description

Company is pre-revenue and pre-commercialization. Seed funding is being used to expand the proprietary data library, team growth, and pursue regulatory approval (FDA, IVDR, CE marking) for AI-powered diagnostic software in MDS, non-small cell lung cancer, and chronic lymphocytic leukemia. Future revenue is expected from a Software as a Medical Device (SaMD) model integrated into diagnostic lab imaging hardware, but no pricing or licensing model is publicly disclosed.

moonlight-ai.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Quote-based / Not publicly disclosed (pre-commercialization)
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing not publicly disclosed; pre-commercialization, regulatory approval pending.

moonlight-ai.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Moonlight AI develops AI-powered diagnostic software that uses computer vision to detect genomic biomarkers and complex disease signatures directly from routine whole slide images of blood, bone marrow, and other cytology smears. The software integrates with diagnostic lab imaging hardware and Laboratory Information Systems to complement and triage conventional molecular testing, delivering faster turnaround times and more automated workflows for hematology and cytopathology. Validated diagnostic applications include sub-2-minute detection of myelodysplastic syndrome from peripheral blood, with ongoing extension to non-small cell lung cancer and chronic lymphocytic leukemia.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Diagnostic results in under 2 minutes vs. 4-5 weeks for traditional MDS testing (bone marrow biopsy + genomic testing)
+2 more records
Product overview1 text field

Moonlight AI offers a single unified AI diagnostics platform — the Moonlight AI Diagnostics Platform — that converts routine microscopic imaging of hematology and cytology smears into genomic insights for hematologists and pathologists. The platform is built on a foundation of multimodal data that pairs whole slide images with genomic results, and is powered by a proprietary Moonlight AI Proprietary Cytopathology Data Library linking whole slide imaging of cytopathology samples with high-quality genomic data. On top of this core platform, validated diagnostic applications such as the MDS Detection from Peripheral Blood (AI Model) demonstrate specific clinical use cases (e.g., detecting myelodysplastic syndrome from neutrophil morphology in peripheral blood in under 2 minutes), with ongoing extension to non-small cell lung cancer and chronic lymphocytic leukemia. The platform integrates with diagnostic lab imaging hardware and Laboratory Information Systems (LIS) via HL7/FHIR to complement and triage conventional molecular testing workflows.

Product and service2 records
1Moonlight AI Diagnostics Platform
CategoryAI Diagnostics Platform (Software as a Medical Device)
Description

AI-powered diagnostics software that uses computer vision to detect genomic biomarkers and complex disease signatures directly from routine imaging of blood, bone marrow, and other cytology smears. The platform integrates with diagnostic lab imaging hardware and Laboratory Information Systems to complement and triage conventional molecular testing such as NGS, providing faster turnaround times and more automated workflows for diagnostic laboratories, hematologists, and pathologists. It is being developed as Software as a Medical Device (SaMD) for indications including myelodysplastic syndrome (MDS), non-small cell lung cancer, and chronic lymphocytic leukemia (CLL).

2MDS Detection from Peripheral Blood (AI Model)
CategoryDiagnostic Application / AI Model for MDS
Description

AI-based diagnostic application that detects myelodysplastic syndrome (MDS) from neutrophil morphology in peripheral blood smears, providing a non-invasive first-line diagnostic result in under 2 minutes. It identifies sub-cellular dysplastic features too subtle for human observers, eliminating or reducing the need for invasive bone marrow biopsies in many cases and enabling faster access to genomic-guided treatment decisions for hematologists.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCore (Founding Clinical Research Partner)TypeStrategic or Co-development Partner
Description

Academic clinical research partner that co-authored Moonlight AI's peer-reviewed Annals of Hematology publication on detecting MDS from peripheral blood. Founder Christian Ruiz is also a Professor at the University of Basel Medical Faculty.

2Universitätsspital Basel
Strategic tierCore (Founding Clinical Research Partner)TypeStrategic or Co-development Partner
Description

University hospital that co-developed and validated Moonlight AI's peripheral blood MDS detection model as part of the initial four-partner consortium.

moonlight-ai.com
3Universitätsspital Zürich
Strategic tierCore (Founding Clinical Research Partner)TypeStrategic or Co-development Partner
Description

University hospital that co-developed and validated Moonlight AI's peripheral blood MDS detection model as part of the initial four-partner consortium.

moonlight-ai.com
Strategic tierCore (Founding Clinical Research Partner)TypeStrategic or Co-development Partner
Description

Berlin university hospital where CMO Dr. Stefan Habringer leads his own research group; co-developed and validated Moonlight AI's peripheral blood MDS detection model as part of the initial consortium.

5DayOne
Strategic tierMinor (Ecosystem Support)TypeOthers
Description

Swiss digital health innovation hub listed under 'Supported by' on the Moonlight AI website, providing regional ecosystem support.

moonlight-ai.com
Strategic tierMinor (Ecosystem Support)TypeOthers
Description

Swiss startup funding program listed under 'Supported by' on the Moonlight AI website, indicating prior non-dilutive or ecosystem support.

Strategic tierMinor (Ecosystem Support)TypeOthers
Description

Regional business promotion agency for the Basel area listed under 'Supported by' on the Moonlight AI website, providing regional ecosystem support.

Strategic tierMinor (Ecosystem Support)TypeOthers
Description

Jura canton economic development agency listed under 'Supported by' on the Moonlight AI website; Moonlight's HQ at Switzerland Innovation Park Basel Area - Jura is located in Courroux, Canton of Jura.

Strategic tierMinor (Ecosystem Support)TypeOthers
Description

University of Basel's startup support initiative listed under 'Supported by' on the Moonlight AI website, providing academic entrepreneurship support.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI biotech using multimodal patient data (including imaging and molecular) to develop diagnostic and therapeutic decision-support tools, with a strong presence in Europe. Comparable in combining imaging-derived AI with molecular insight for oncology decision support.

2Tempus Labs
TypeBroad incumbent
Description

Large US AI-driven precision medicine company combining molecular profiling, imaging and clinical data for oncology decision support. Comparable end goal (imaging + genomics for cancer) but much broader portfolio and substantially more capital than Moonlight AI.

3Aignostics
TypeDirect peer
Description

Berlin-based AI pathology company spun out of Charit\u00e9, building foundation models for pathology image analysis and partnering with pharma and diagnostic labs. Comparable European AI-pathology peer with similar academic origins and lab-embedded go-to-market.

TypeBroad incumbent
Description

Subsidiary of RadNet applying AI to medical imaging and diagnostics, with FDA-cleared products and broad imaging footprint. Comparable as an AI imaging diagnostics platform, though focused on radiology rather than pathology/hematology.

TypeDirect peer
Description

Israel-based AI pathology company with multiple CE-marked and deployed products for cancer detection in routine pathology workflows. Closest pure-play peer to Moonlight's lab-embedded, image-based SaMD model for oncology diagnostics.

TypeDirect peer
Description

AI-driven digital pathology platform with FDA-cleared products for prostate and breast cancer. Directly comparable to Moonlight AI as both build deep learning models that derive molecular / diagnostic insight from whole slide images and pursue SaMD clearance in oncology.

TypeBroad incumbent
Description

South Korea-based AI medical imaging company with cleared products for chest X-ray, mammography and pathology biomarker prediction (e.g., Lunit SCOPE). Comparable in applying deep learning to histology/biomarker prediction, though broader in scope and modality coverage.

TypeDirect peer
Description

AI pathology company developing deep learning models on whole slide images for diagnostic and biomarker applications across oncology. Highly comparable business model: AI + pathology + clinical partnerships + pharma services, also pre-commercial / clinical-stage.

TypeEmerging player
Description

Stockholm-based AI precision diagnostics company focused on AI-based prognostic and predictive biomarker profiling from routine histopathology images. Comparable as a European SaMD peer using image-only AI to derive molecular-grade insight for oncology treatment decisions.

TypeDirect peer
Description

Digital pathology software platform with AI applications for cancer diagnosis and biomarker detection, integrating with lab imaging hardware and LIS environments. Comparable as an enterprise pathology software company with embedded AI diagnostics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Moonlight AI

AI Diagnostics Softwaremoonlight-ai.com

Moonlight AI is a Swiss AI diagnostics startup that uses computer vision and deep learning on whole slide images of hematology and cytology smears to detect genomic biomarkers, serving diagnostic laboratories, hematologists, and pathologists with plans for Software as a Medical Device products across MDS, NSCLC and CLL.

What Moonlight AI does

Moonlight AI is a Swiss AI diagnostics company, founded in 2022 and headquartered at the Switzerland Innovation Park Basel Area - Jura in Courroux, with operational offices in Basel (engineering, ML, technical program management) and Tunis (clinical operations, data management, engineering). The company builds a computer-vision and deep-learning platform that analyzes whole slide images of hematology and cytology smears to detect genomic biomarkers and complex disease signatures directly from routine imaging, intended to triage and complement conventional molecular testing such as NGS in diagnostic laboratory workflows. Its product surface currently centers on a myelodysplastic syndrome (MDS) detection capability from peripheral blood, published in Annals of Hematology in June 2025, with planned extension to non-small cell lung cancer (NSCLC) and chronic lymphocytic leukemia (CLL). The platform is designed to integrate with diagnostic lab imaging hardware and Laboratory Information Systems via HL7/FHIR/DICOM and is being engineered for on-premises, cloud, or OEM-embedded deployment aligned with ISO 27001, HIPAA, GDPR and FDA/IVDR/CE regulatory requirements.

Moonlight AI is pre-revenue and pre-commercialization. Its economic model is planned Software as a Medical Device (SaMD) licensing integrated into lab imaging hardware and connected to LIS, with go-to-market executed through direct enterprise sales to diagnostic labs and hospitals plus an international clinical consortium that co-develops and validates the platform in real-world settings; no pricing or contract terms are publicly disclosed. The company serves three primary segments: diagnostic laboratories (the B2B buyer), and the user personas of hematologists and pathologists who consume the diagnostic insight. Four founding clinical partners — University of Basel, Universitätsspital Basel, Universitätsspital Zürich and Charité Universitätsmedizin Berlin — support the initial MDS validation, and a Tunis-based Clinical Study Manager is building additional partnerships across MENA and Europe. On May 6, 2026, the company closed a $3.3M USD seed round co-led by Lotus One Investment (Singapore), VP Venture Partners (Switzerland) and MEDIN Fund (Tunisia), with N&V Capital and existing investor QAI Ventures participating, and simultaneously reincorporated from a Swiss GmbH to a Swiss Stock Corporation (Aktiengesellschaft) to position for international commercialization.

Moonlight AI firmographics

Firmographics
Name
Moonlight AI
Legal name
Moonlight AI AG
Website
https://moonlight-ai.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
1–10 employees
Short description
Moonlight AI is a Swiss AI diagnostics startup that uses computer vision and deep learning on whole slide images of hematology and cytology smears to detect genomic biomarkers, serving diagnostic laboratories, hematologists, and pathologists with plans for Software as a Medical Device products across MDS, NSCLC and CLL.
Ownership category
akta.pro rank

Moonlight AI industry classification

Industry
Product category
AI Diagnostics Software
NAICS
Other Computer Related Services (541519), Computer Systems Design and Related Services (54151)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLACANAD
Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT

Keywords

  • AI diagnostics software
  • Computational pathology
  • Whole slide imaging
  • Genomic biomarker detection
  • Hematology image analysis

Where Moonlight AI is headquartered

Location

Headquarters

HQ city
Courroux
HQ country
Switzerland
HQ region
Europe

Offices3 records

Markets served

Moonlight AI business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pre-commercialization software diagnostics (planned): Company is pre-revenue and pre-commercialization. Seed funding is being used to expand the proprietary data library, team growth, and pursue regulatory approval (FDA, IVDR, CE marking) for AI-powered diagnostic software in MDS, non-small cell lung cancer, and chronic lymphocytic leukemia. Future revenue is expected from a Software as a Medical Device (SaMD) model integrated into diagnostic lab imaging hardware, but no pricing or licensing model is publicly disclosed.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based / Not publicly disclosed (pre-commercialization)

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Moonlight AI product offering

Product offering

Core offering

Moonlight AI develops AI-powered diagnostic software that uses computer vision to detect genomic biomarkers and complex disease signatures directly from routine whole slide images of blood, bone marrow, and other cytology smears. The software integrates with diagnostic lab imaging hardware and Laboratory Information Systems to complement and triage conventional molecular testing, delivering faster turnaround times and more automated workflows for hematology and cytopathology. Validated diagnostic applications include sub-2-minute detection of myelodysplastic syndrome from peripheral blood, with ongoing extension to non-small cell lung cancer and chronic lymphocytic leukemia.

Product overview

Moonlight AI offers a single unified AI diagnostics platform — the Moonlight AI Diagnostics Platform — that converts routine microscopic imaging of hematology and cytology smears into genomic insights for hematologists and pathologists. The platform is built on a foundation of multimodal data that pairs whole slide images with genomic results, and is powered by a proprietary Moonlight AI Proprietary Cytopathology Data Library linking whole slide imaging of cytopathology samples with high-quality genomic data. On top of this core platform, validated diagnostic applications such as the MDS Detection from Peripheral Blood (AI Model) demonstrate specific clinical use cases (e.g., detecting myelodysplastic syndrome from neutrophil morphology in peripheral blood in under 2 minutes), with ongoing extension to non-small cell lung cancer and chronic lymphocytic leukemia. The platform integrates with diagnostic lab imaging hardware and Laboratory Information Systems (LIS) via HL7/FHIR to complement and triage conventional molecular testing workflows.

Differentiator

Problem solved

Functional benefit

Products and services

  • Moonlight AI Diagnostics Platform AI-powered diagnostics software that uses computer vision to detect genomic biomarkers and complex disease signatures directly from routine imaging of blood, bone marrow, and other cytology smears. The platform integrates with diagnostic lab imaging hardware and Laboratory Information Systems to complement and triage conventional molecular testing such as NGS, providing faster turnaround times and more automated workflows for diagnostic laboratories, hematologists, and pathologists. It is being developed as Software as a Medical Device (SaMD) for indications including myelodysplastic syndrome (MDS), non-small cell lung cancer, and chronic lymphocytic leukemia (CLL).
  • MDS Detection from Peripheral Blood (AI Model) AI-based diagnostic application that detects myelodysplastic syndrome (MDS) from neutrophil morphology in peripheral blood smears, providing a non-invasive first-line diagnostic result in under 2 minutes. It identifies sub-cellular dysplastic features too subtle for human observers, eliminating or reducing the need for invasive bone marrow biopsies in many cases and enabling faster access to genomic-guided treatment decisions for hematologists.

Quantifiable outcome

  • Diagnostic results in under 2 minutes vs. 4-5 weeks for traditional MDS testing (bone marrow biopsy + genomic testing)
  • +2 more outcomes

Companies that use Moonlight AI

Customer profile

Segments4 records

Ideal customer profiles4 records

Moonlight AI technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability6 records

Feature4 records

Moonlight AI partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core (founding clinical research partner) and minor (ecosystem support).

  • University of Baselcore (founding clinical research partner)Strategic or Co-development PartnerAcademic clinical research partner that co-authored Moonlight AI's peer-reviewed Annals of Hematology publication on detecting MDS from peripheral blood. Founder Christian Ruiz is also a Professor at the University of Basel Medical Faculty.
  • Universitätsspital Baselcore (founding clinical research partner)Strategic or Co-development PartnerUniversity hospital that co-developed and validated Moonlight AI's peripheral blood MDS detection model as part of the initial four-partner consortium.
  • Universitätsspital Zürichcore (founding clinical research partner)Strategic or Co-development PartnerUniversity hospital that co-developed and validated Moonlight AI's peripheral blood MDS detection model as part of the initial four-partner consortium.
  • Charité Universitätsmedizin Berlincore (founding clinical research partner)Strategic or Co-development PartnerBerlin university hospital where CMO Dr. Stefan Habringer leads his own research group; co-developed and validated Moonlight AI's peripheral blood MDS detection model as part of the initial consortium.
  • DayOneminor (ecosystem support)OthersSwiss digital health innovation hub listed under 'Supported by' on the Moonlight AI website, providing regional ecosystem support.
  • VentureKickminor (ecosystem support)OthersSwiss startup funding program listed under 'Supported by' on the Moonlight AI website, indicating prior non-dilutive or ecosystem support.
  • Basel Areaminor (ecosystem support)OthersRegional business promotion agency for the Basel area listed under 'Supported by' on the Moonlight AI website, providing regional ecosystem support.
  • Jura Promotion Economiqueminor (ecosystem support)OthersJura canton economic development agency listed under 'Supported by' on the Moonlight AI website; Moonlight's HQ at Switzerland Innovation Park Basel Area - Jura is located in Courroux, Canton of Jura.
  • University of Basel Startupminor (ecosystem support)OthersUniversity of Basel's startup support initiative listed under 'Supported by' on the Moonlight AI website, providing academic entrepreneurship support.

Scale indicators8 records

Recent moves6 records

Expansion highlights7 records

Moonlight AI competitors and assessment

Company assessment

Direct peers

  • Owkin: AI biotech using multimodal patient data (including imaging and molecular) to develop diagnostic and therapeutic decision-support tools, with a strong presence in Europe. Comparable in combining imaging-derived AI with molecular insight for oncology decision support.
  • Aignostics: Berlin-based AI pathology company spun out of Charit\u00e9, building foundation models for pathology image analysis and partnering with pharma and diagnostic labs. Comparable European AI-pathology peer with similar academic origins and lab-embedded go-to-market.
  • Ibex Medical Analytics: Israel-based AI pathology company with multiple CE-marked and deployed products for cancer detection in routine pathology workflows. Closest pure-play peer to Moonlight's lab-embedded, image-based SaMD model for oncology diagnostics.
  • Paige AI: AI-driven digital pathology platform with FDA-cleared products for prostate and breast cancer. Directly comparable to Moonlight AI as both build deep learning models that derive molecular / diagnostic insight from whole slide images and pursue SaMD clearance in oncology.
  • PathAI: AI pathology company developing deep learning models on whole slide images for diagnostic and biomarker applications across oncology. Highly comparable business model: AI + pathology + clinical partnerships + pharma services, also pre-commercial / clinical-stage.
  • Proscia: Digital pathology software platform with AI applications for cancer diagnosis and biomarker detection, integrating with lab imaging hardware and LIS environments. Comparable as an enterprise pathology software company with embedded AI diagnostics.

Broad incumbents

  • Tempus Labs: Large US AI-driven precision medicine company combining molecular profiling, imaging and clinical data for oncology decision support. Comparable end goal (imaging + genomics for cancer) but much broader portfolio and substantially more capital than Moonlight AI.
  • DeepHealth (RadNet): Subsidiary of RadNet applying AI to medical imaging and diagnostics, with FDA-cleared products and broad imaging footprint. Comparable as an AI imaging diagnostics platform, though focused on radiology rather than pathology/hematology.
  • Lunit: South Korea-based AI medical imaging company with cleared products for chest X-ray, mammography and pathology biomarker prediction (e.g., Lunit SCOPE). Comparable in applying deep learning to histology/biomarker prediction, though broader in scope and modality coverage.

Emerging players

  • Stratipath: Stockholm-based AI precision diagnostics company focused on AI-based prognostic and predictive biomarker profiling from routine histopathology images. Comparable as a European SaMD peer using image-only AI to derive molecular-grade insight for oncology treatment decisions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Moonlight AI social profiles

Digital presence

Moonlight AI compliance and trust

Trust signal

Compliance5 records

Moonlight AI financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Moonlight AI leadership team

Management profile

Number of profiles

Profiles4 records

Moonlight AI funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Moonlight AI M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Moonlight AI

What does Moonlight AI do?

Moonlight AI develops AI-powered diagnostic software that uses computer vision to detect genomic biomarkers and complex disease signatures directly from routine whole slide images of blood, bone marrow, and other cytology smears. The software integrates with diagnostic lab imaging hardware and Laboratory Information Systems to complement and triage conventional molecular testing, delivering faster turnaround times and more automated workflows for hematology and cytopathology. Validated diagnostic applications include sub-2-minute detection of myelodysplastic syndrome from peripheral blood, with ongoing extension to non-small cell lung cancer and chronic lymphocytic leukemia.

Is Moonlight AI a public or private company?

Moonlight AI is a private company. It is classified as venture growth investor backed and is currently operating.

When was Moonlight AI founded?

Moonlight AI was founded in 2022. It employs 1 to 10 people.

Where is Moonlight AI based?

Moonlight AI is headquartered in Courroux, Switzerland, in the Europe region.

How does Moonlight AI make money?

One revenue line is on record: pre-commercialization software diagnostics (planned).

Who are Moonlight AI's main competitors?

Direct peers on record are Owkin, Aignostics, Ibex Medical Analytics, Paige AI, PathAI and Proscia. Broad incumbents are Tempus Labs, DeepHealth (RadNet) and Lunit. Stratipath is listed as an emerging player.

Does Moonlight AI have an API?

Yes. The company is building backend services and APIs supporting clinical workflows and platform functionality, including integrations with Laboratory Information Systems (LIS) using HL7 / FHIR healthcare interoperability standards. The platform is designed to expose APIs for clinical partners and lab integrations. No public developer portal, documentation, SDK, or MCP server was identified.

What industry is Moonlight AI in?

Moonlight AI's product category is AI Diagnostics Software. Its primary akta.pro industry code is HLACANAD, Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software, with a secondary code of HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML). Its NAICS code is 541519 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The SaaS NewsMoonlight AI Raises €2.8M SeedMoonlight AI, a Swiss AI diagnostics startup, closed a €2.8 million seed round co-led by Lotus One Investment, VP Venture Partners, and MEDIN Fund. The funds will expand its proprietary data library and develop diagnostic solutions for conditions like myelodysplastic syndrome and lung cancer.AI InsiderMoonlight AI Raises $3.3M to Deploy Computer Vision for Faster Cancer DiagnosticsSwiss startup Moonlight AI has raised $3.3 million in seed funding co-led by Lotus One Investment, VP Venture Partners, and MEDIN Fund, with participation from N&V Capital and QAI Ventures, to advance AI-powered image analysis for clinical oncology diagnostics. The company's computer vision platform detects genomic biomarkers directly from routine blood and cytology slide imaging, targeting hematologists and pathologists treating blood cancers including MDS, chronic lymphocytic leukemia, and non-small cell lung cancer. The funding will support expansion of a proprietary dataset linking whole slide imaging with genomic data, team growth, and regulatory approval processes.Pulse 2.0Moonlight AI: $3.3 Million Seed Round Raised For AI-Powered Hematology Diagnostics PlatformMoonlight AI AG secured $3.3 million in seed funding to develop AI software for hematology and oncology diagnostics. The funding will support expanding proprietary datasets, accelerating commercialization, and developing targeted diagnostic solutions.startupticker.chWhy the healthcare sector is thrivingThe Swiss Biotech Report shows the sector thriving despite a strong franc and tariff threats, with turnover, employment, and company numbers growing. Windward Bio raised USD 165 million, while Moonlight AI and Bioscibex also secured funding. The report cites increasing ecosystem maturity and AI-driven opportunities.EU-StartupsSwiss startup Moonlight AI raises €2.8 million to turn routine blood and cytology imaging into genomic insightsSwiss startup Moonlight AI has closed a €2.8 million Seed funding round co-led by Lotus One Investment, VP Venture Partners, and MEDIN Fund, with participation from N&V Capital and existing investor QAI Ventures. The company, founded in 2022, develops AI-based diagnostics software that converts medical images of blood and cytology smears into genomic insights to help pathologists make faster cancer treatment decisions. Moonlight AI plans to use the funding to expand its proprietary data library, develop diagnostic solutions for myelodysplastic syndrome, non-small cell lung cancer, and chronic lymphocytic leukaemia, and accelerate its path to commercialization and regulatory approval.Moonlight-AiMoonlight AI AG Raises $3.3M Seed Round to Transform Hematology Labs with AI-Powered DiagnosticsMoonlight AI AG, a Swiss startup, closed a $3.3 million seed round co-led by Lotus One Investment, VP Venture Partners, and MEDIN Fund. The funding will expand its cytopathology dataset and develop diagnostics for MDS, lung cancer, and CLL. The company is transitioning into a Swiss Stock Corporation for international expansion.BebeezSwiss startup Moonlight AI raises €2.8 million to turn routine blood and cytology imaging into genomic insights – BeBeez InternationalMoonlight AI, a Swiss startup developing AI-driven diagnostics software for clinical-grade cancer detection, has closed a €2.8 million Seed funding round co-led by Lotus One Investment, VP Venture Partners, and MEDIN Fund, with participation from N&V Capital and existing investor QAI Ventures. The company converts routine blood and cytology images into genomic insights to help hematologists and pathologists make faster, more accurate treatment decisions for cancer patients, addressing bottlenecks in precision oncology caused by high costs of Next-Generation Sequencing. The funding will be used to expand the company's proprietary data library, grow the team, advance diagnostic solutions for myelodysplastic syndrome, non-small cell lung cancer, and chronic lymphocytic leukemia, and accelerate commercialization and regulatory approval.startupticker.chMoonlight AI raises $3.3 million to transform hematology labs with AI-powered diagnosticsMoonlight AI, a Swiss startup, closed a $3.3 million seed round to fund AI-powered diagnostics for hematology labs. The company uses computer vision to detect genomic biomarkers from routine blood smears, aiming to speed cancer treatment decisions. Funds will expand its data library and develop solutions for MDS, lung cancer, and CLL.FRENCHWEB.FRMOONLIGHT AI lève 2,8 millions d’euros pour accélérer le diagnostic du cancer par IAMoonlight AI, a Swiss startup, raised €2.8 million in seed funding to develop AI software for cancer diagnostics from medical images. The company aims to replace costly next-generation sequencing by detecting biomarkers from routine cytology slides. It is building a proprietary database of cytopathology and genomic data.